ModifiedEmblemHealthPolicy MG.MM.PH.345

Saphnelo (anifrolumab-fnia) Intravenous

Policy governing medical necessity and authorization criteria for Saphnelo (anifrolumab-fnia) IV in adults with moderate to severe systemic lupus erythematosus (SLE) receiving standard therapy for EmblemHealth members.

Policy Summary

PayerEmblemHealth

PolicySaphnelo (anifrolumab-fnia) Intravenous

Policy CodePolicy MG.MM.PH.345

Change TypeMaterial clinical and operational updates

Effective Date

Next Review DateFeb 18, 2025

Key ActionSubmit prior authorization with documentation of age >18, confirmed SLE diagnosis (classification score ≥10 including clinical and immunologic domains), ANA ≥1:80, baseline disease activity assessment, and evidence of concurrent standard therapy or intolerance.

SourceLink

POLICY UPDATE CHANGES

Length of authorization updated to 12 months (replaced prior split of 6 months initial / 1 year continuation).

Initial criteria reworded to require confirmed SLE classification criteria score >= 10 including clinical and immunologic domains and ANA titer >= 1:80, documentation of active disease, baseline objective disease severity assessment, and requirement for concurrent standard therapy unless intolerant.

Explicit exclusion for severe active central nervous system lupus and severe active lupus nephritis.

Continuation criteria defined to require absence of unacceptable toxicity and objective evidence of disease stability or improvement (SELENA-SLEDAI-2K, BILAG-2004, PGA).

Continuation criteria clarified to require patients to continue to meet universal and indication-specific criteria, absence of unacceptable toxicity, and documentation of disease stability or improvement using specified disease activity measures.

12 monthsLength of authorization

300 mg

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Saphnelo (anifrolumab-fnia)

Initial Approval Criteria

Covered when ALL of the following are met:

Initial Approval: Patient is > 18 years of age.

Disease severity or intolerance: Patient meets ONE of the following: (i) has moderate to severe systemic lupus erythematosus and the medication is being used concurrently with at least one other standard therapy (e.g., antimalarial, systemic corticosteroid, or other immunosuppressant) OR (ii) patient is intolerant to standard therapy due to significant toxicity as determined by the prescriber.

For patients already established on biologic therapy, trial and failure of standard therapy is not required.

Prescriber and concomitant biologic use: Medication is prescribed by or in consultation with a rheumatologist, clinical immunologist, nephrologist, neurologist, or dermatologist; and will NOT be used concurrently with other biologics (e.g., belimumab, rituximab).

Exclusions: Patient does not have any of the following exclusion criteria: severe active central nervous system lupus OR severe active lupus nephritis.

Confirmed diagnosis: Patient has a confirmed diagnosis of SLE evidenced by ALL of the following: a confirmed SLE classification criteria score >= 10 (must include clinical and immunologic domains) AND an anti-nuclear antibody (ANA) titer >= 1:80 measured by indirect immunofluorescence (IIF) on Hep-2 cells or equivalent at least once.>= 10 for classification score; ANA >= 1:80

Active disease and baseline assessment: Patient has documented active disease AND the physician has assessed baseline disease severity using an objective measure/tool (SLEDAI-2K, BILAG-2004, and/or Physician's Global Assessment [PGA]).

Baseline objective disease severity assessment must be submitted.

Prior therapy failure: Patient has failed to respond adequately to at least one standard therapy (e.g., antimalarials, corticosteroids, or immunosuppressives), unless patient is already established on biologic therapy where prior standard therapy trial is not required.

Continuation (Renewal) Criteria

Covered when ALL of the following are met during the authorization period:

Continuation - Universal criteria: Patient continues to meet the universal and other indication-specific relevant criteria identified in the initial approval (including concomitant therapy requirements and prescriber specialty).

Absence of unacceptable toxicity: There is absence of unacceptable toxicity from the drug (examples include serious infections, malignancy, severe hypersensitivity reactions/anaphylaxis).

Objective evidence of stability or improvement: Adequate documentation of disease stability or improvement compared to pre-treatment baseline demonstrated by one or more of the following measures:

Measures listed as children

SELENA-SLEDAI-2K: Improvement in the SELENA-SLEDAI-2K compared to pre-treatment baseline.

Continuation Therapy

Covered when ALL of the following are met for continuation:

Universal and indication-specific criteria: Patient continues to meet the universal and other indication-specific relevant criteria identified in the initial approval (such as concomitant therapy requirements).

Absence of unacceptable toxicity: No unacceptable toxicity from the drug (examples include serious infections, malignancy, severe hypersensitivity/anaphylaxis).

Examples include serious infections, malignancy, severe hypersensitivity/anaphylaxis.

Documentation of disease stability or improvement: Adequate documentation of disease stability and/or improvement compared to pre-treatment baseline demonstrated by one or more of the following measures:

SELENA-SLEDAI-2K improvement: Improvement in the SELENA-SLEDAI-2K when compared to pre-treatment baseline.

Saphnelo is not to be used in patients with severe active central nervous system lupus or severe active lupus nephritis. These conditions are explicit exclusions to coverage and must be absent for initial or continued authorization.

The appendix lists biologic agents and indications for reference but is not an all-inclusive list. Refer to each product’s prescribing information for FDA‑approved indications and other agent‑specific considerations (oncology and less common inflammatory indications may not be listed).

Clinical evidence is limited for patients with severe active lupus nephritis or severe active central nervous system lupus; efficacy has not been evaluated and use is not recommended in these populations. Clinicians should avoid initiating Saphnelo for these severe disease manifestations.

Continuation requests that do not include documentation demonstrating continued clinical benefit using the required measures, or that document unacceptable toxicity, should be considered as not meeting continuation criteria. Requests submitted without supporting clinical evidence of ongoing benefit or with evidence of serious adverse events (for example, serious infections, malignancy, or severe hypersensitivity/anaphylaxis) may be denied or not properly reviewed.

Coding and Identifiers

Applicable HCPCS CodesHCPCSCovered

J0491

Saphnelo 300MG/2ML Solution J0491 Injection, anifrolumab-fnia, 1 mg

Applicable NDCsNDC

00310-3040-00

Solution, 300 mg/2 mL, one single dose vial

Applicable ICD-10 DiagnosesICD-10

M32.10	Systemic lupus erythematosus, organ or system involvement unspecified
M32.11	Endocarditis in systemic lupus erythematosus
M32.12	Pericarditis in systemic lupus erythematosus
M32.13	Lung involvement in systemic lupus erythematosus
M32.14	Glomerular disease in systemic lupus erythematosus
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus
M32.19	Other organ or system involvement in systemic lupus erythematosus
M32.8	Other forms of systemic lupus erythematosus
M32.9	Systemic lupus erythematosus, unspecified

Policy-level billing code changesHCPCS

J0491	Added code during template transfer
C9086	Removed code
J3590	Removed code

Appendix: Biologics and indications (not exhaustive)mixed

belimumab (SC/IV)	BLyS inhibitor; indicated for SLE, lupus nephritis
adalimumab (SC)	TNF inhibitor; indicated for AS, CD, JIA, HS, PsO, PsA, RA, UC, UV
certolizumab pegol (SC)	TNF inhibitor; indicated for AS, CD, nr-axSpA, PsO, PsA, RA
etanercept (SC)	TNF inhibitor; indicated for RA
infliximab (IV)	TNF inhibitor; indicated for RA, UC
golimumab (SC/IV)	TNF inhibitor; indications vary by formulation
tocilizumab (IV/SC)	IL-6 inhibitor; indications include RA, PJIA, SJIA
sarilumab (SC)	IL-6 inhibitor; indicated for RA
abatacept (IV/SC)	T-cell costimulation modulator; indicated for JIA, PsA, RA
rituximab (IV)	CD20-directed cytolytic antibody; indicated for RA

1–10 of 19

1/2

SLE classification score — required threshold and domain inclusion to confirm diagnosis

Required score>= 10 on the confirmed SLE classification criteria

Domain requirementScore must include both clinical and immunologic domains

Source toolWeb-based weighted scoring system across 10 domains (7 clinical, 3 immunologic)

ANA titer — required threshold (method specified)

Required ANA titer>= 1:80

Method specified

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization for Continuation Therapy

Prior authorization is required for continuation therapy. Providers must submit a continuation request demonstrating that the member continues to meet the universal and indication-specific criteria identified in the initial approval (including concomitant therapy requirements, performance status, and other relevant items).

Prior authorization required for continuation requests

Denial Risk

Denial Risk for Continuation Requests

Continuation requests that do not document ongoing fulfillment of continuation criteria, evidence of unacceptable toxicity, or objective measures of disease stability or improvement may be denied. Providers should be aware that absence of required evidence will place the request at risk for denial or pend.

Denial risk if documentation of continued criteria is missing

Background

Saphnelo (anifrolumab‑fnia) is a type I interferon receptor antagonist indicated for adults with moderate to severe systemic lupus erythematosus who are receiving standard therapy. It is administered as a 300 mg intravenous infusion every 4 weeks; efficacy has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus.

Definitions and Abbreviations

Confirmed SLE classification criteria score — explanation of the web-based weighted scoring system and domain requirements

What it isA web-based weighted scoring system across 10 domains (7 clinical, 3 immunologic)

Required threshold>= 10 points to confirm SLE classification

Domain inclusionScore must include criteria from both clinical and immunologic domains to be valid

ReferenceReferenced web calculator: rheumatology.org/criteria (per policy definitions)

BLyS — definition (B-lymphocyte stimulator-specific inhibitor)

DefinitionBLyS = B-lymphocyte stimulator-specific inhibitor (example: belimumab)

Policy Summary

PayerEmblemHealth

PolicySaphnelo (anifrolumab-fnia) Intravenous

Policy CodePolicy MG.MM.PH.345

Change TypeMaterial clinical and operational updates

Effective Date

Next Review DateFeb 18, 2025

SourceLink

On This Page

Documentation Required

Required Documentation for Continuation

For continuation authorization, providers must document continued fulfillment of the criteria that supported initial approval, absence of unacceptable toxicity, and objective measures showing stability or clinical improvement compared to baseline.

Documentation that patient continues to meet universal and indication-specific criteria from initial approval
Documentation of absence of unacceptable toxicity (examples: serious infections, malignancy, severe hypersensitivity/anaphylaxis)
Objective measures of stability or improvement such as: improvement in SELENA-SLEDAI-2K; reduction in baseline BILAG-2004 (e.g., from A to B or B to C/D) without worsening in other organ systems; no worsening (<0.30 point increase) in Physician's Global Assessment (PGA); or seroconversion to negative

Prior Authorization

Concomitant Standard Therapy Requirement

The patient must be receiving the medication concurrently with at least one standard therapy (for example an antimalarial like hydroxychloroquine, systemic corticosteroid such as prednisone, or an immunosuppressant like azathioprine, mycophenolate mofetil, or methotrexate) unless the prescriber documents that the patient is intolerant to standard therapy due to significant toxicity.

Concurrent use with ≥1 standard therapy required unless documented intolerance to standard therapy by prescriber